Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRBO
DateTimeSourceHeadlineSymbolCompany
10/01/202513:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/12/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/12/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
29/11/202414:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/11/202413:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
18/11/202413:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
15/11/202413:35GlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/11/202413:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/11/202421:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/11/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/11/202413:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/11/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/11/202413:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/10/202411:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/10/202412:01PR Newswire (US)NeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/09/202412:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
30/09/202412:01PR Newswire (US)NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
20/09/202420:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
20/09/202420:15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
19/09/202420:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/09/202412:01PR Newswire (US)NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
21/08/202420:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202421:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
14/08/202412:01PR Newswire (US)NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202420:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
13/08/202412:01PR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/08/202412:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/08/202412:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRBO